Valuation: Natera, Inc.

Market Cap 40.37B 35.31B 32.56B 30.13B 57.19B 3,853B 58.14B 390B 153B 1,892B 152B 148B 6,554B P/E 2026 *
-170x
P/E 2027 * -1,185x
Enterprise Value 39.34B 34.42B 31.74B 29.36B 55.74B 3,755B 56.67B 380B 149B 1,844B 148B 144B 6,388B EV / Sales 2026 *
14.1x
EV / Sales 2027 * 11.7x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day+2.72%
1 week+0.91%
Current month+3.83%
1 month+26.49%
3 months+38.84%
6 months+20.29%
Current year+23.03%
1 week 269.66
Extreme 269.66
288.04
1 month 208.79
Extreme 208.794
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Founder

-1,000 0.0007%
06-30Sell

General Counsel

-16,800 0.0117%
06-30Sell

Executive/Senior Manager

-3,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%+0.91%+74.25%+501.09% 40.37B
-0.04%-3.26%+7.16%+33.30% 22.77B
-0.56%-0.05%-21.62%-38.20% 7.33B
+0.53%-4.09%+14.44%+111.35% 5.19B
+0.49%+2.87%+15.58%+41.53% 2.95B
+5.75%+2.78%-24.48%+1,166.24% 2.06B
+3.44%-2.84%+95.62%-6.65% 1.92B
-1.98%-9.70%+24.25%-26.35% 1.65B
+2.21%-0.19%+22.57%-2.84% 1.67B
-0.30%-2.26%-17.96%-69.06% 1.56B
Average +1.23%-1.59%+18.98%+171.04% 8.74B
Weighted average by Cap. +1.46%-0.67%+37.80%+270.31%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.26B 2.09B 3.96B 267B 4.03B 27.03B 10.6B 131B 10.5B 10.28B 454B 3.33B 2.91B 2.68B 2.48B 4.71B 318B 4.79B 32.14B 12.6B 156B 12.49B 12.22B 540B
Net income -224M -196M -181M -167M -318M -21.39B -323M -2.17B -849M -10.51B -841M -823M -36.39B -28.48M -24.91M -22.97M -21.25M -40.34M -2.72B -41.02M -275M -108M -1.33B -107M -105M -4.62B
Net Debt -1.02B -896M -826M -764M -1.45B -97.73B -1.47B -9.89B -3.88B -47.99B -3.84B -3.76B -166B -1.3B -1.14B -1.05B -973M -1.85B -124B -1.88B -12.59B -4.94B -61.09B -4.89B -4.79B -212B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-09 US$281.85 +2.72% 1,958,307
26-07-08 US$274.39 -2.45% 1,398,594
26-07-07 US$281.27 -0.89% 1,759,681
26-07-06 US$283.80 +1.60% 1,358,559
26-07-02 US$279.32 +1.10% 1,274,247
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
281.85USD
Average target price
271.24USD
Spread / Average Target
-3.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock